{"id":2534,"date":"2026-08-19T07:00:53","date_gmt":"2026-08-18T23:00:53","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2534"},"modified":"2026-08-18T18:13:04","modified_gmt":"2026-08-18T10:13:04","slug":"hanchorbio-announces-hcb301-oral-presentation-and-hcb101-best-poster-selection-at-ksmo-2026","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-announces-hcb301-oral-presentation-and-hcb101-best-poster-selection-at-ksmo-2026\/","title":{"rendered":"HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026"},"content":{"rendered":"

HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026<\/strong><\/h2>\n

Three abstracts accepted across HCB101 and HCB301,
\nincluding the gastric cancer Best Poster Presentation Award and Poster Discussion<\/em><\/h3>\n

TAIPEI, SHANGHAI, and SAN FRANCISCO \u2014\u00a0August 19, 2026<\/strong>\u00a0\u2014 HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at\u00a0KSMO 2026\u2014<\/strong>the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference\u2014<\/strong>held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO)<\/strong>, taking place September 2\u20134, 2026, in Seoul, Korea.<\/p>\n

 <\/p>\n

The presentations include two posters on HCB101 clinical development in\u00a0gastric cancer (GC)\u00a0and\u00a0head and neck squamous cell carcinoma (HNSCC), as well as an\u00a0oral presentation of first-in-human clinical data for HCB301, HanchorBio’s tri-specific SIRP\u03b1\u2013PD-L1\u2013TGF\u03b2 fusion protein.<\/p>\n

 <\/p>\n

The HCB101 gastric cancer abstract has also been selected for the\u00a0KSMO 2026 Best Poster Presentation Award and a Poster Discussion presentation<\/strong>. According to KSMO, only outstanding abstracts were selected for the Poster Discussion sessions.<\/p>\n

 <\/p>\n

\u201cWe are pleased to have three clinical presentations selected for KSMO 2026 and FACO across two programs from our FBDB\u2122 platform,\u201d said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio<\/strong>. \u201cHCB101 and HCB301 represent our innovative approaches to overcoming immune resistance, from activating macrophage-mediated antitumor immunity to integrating and synergizing multiple immune pathways within a single therapeutic molecule. We look forward to sharing our progress with the oncology community in Seoul.\u201d<\/p>\n

 <\/p>\n

Alvin Luk, Ph.D., M.B.A., C.C.R.A., President and Chief Medical Officer (Group) & CEO (USA) of HanchorBio<\/strong>, will deliver the HCB301 oral presentation.<\/p>\n

 <\/p>\n

HanchorBio Presentations at KSMO 2026 \/ FACO<\/strong><\/p>\n

    \n
  • HCB101 \u2014 Gastric Cancer<\/strong>
    \nPreliminary Antitumor Activity of HCB101 (SIRP\u03b1-Fc Fusion Protein)-Based Combination Therapy in Advanced Gastric Cancer<\/em><\/p>\n
      \n
    • Presentation:<\/strong> Best Poster Presentation Award \/ Poster Discussion (In-Person Presentation)<\/li>\n
    • Date:<\/strong>September 3, 2026<\/li>\n
    • Poster Discussion Session:<\/strong>14:50\u201315:20 KST<\/li>\n
    • Presentation Format:<\/strong>4-minute presentation + 2-minute real-time Q&A<\/li>\n
    • Presentation Code\/Location:<\/strong> PD01\/Carnation Room (5 Floor)<\/li>\n<\/ul>\n<\/li>\n
    • HCB101 \u2014 Head and Neck Squamous Cell Carcinoma<\/strong>
      \nHCB101 in HNSCC: Early Clinical Evidence Supporting PD-1- and EGFR-Directed Combination Strategies<\/em><\/p>\n
        \n
      • Presentation:<\/strong>Poster<\/li>\n
      • Date:<\/strong>September 3, 2026<\/li>\n<\/ul>\n<\/li>\n
      • HCB301 \u2014 First-in-Human Phase 1 Study<\/strong>
        \nCoordinated SIRP\u03b1-PD-L1-TGF\u03b2 Modulation with HCB301: Early Safety and Disease Control in a First-in-Human Phase 1 Study<\/em><\/p>\n
          \n
        • Presentation:<\/strong>Oral Presentation (In-Person Presentation)<\/li>\n
        • Presenter:<\/strong>Alvin Luk, Ph.D., M.B.A., C.C.R.A.<\/li>\n
        • Date:<\/strong>September 4, 2026<\/li>\n
        • Session:<\/strong>14:40\u201315:40 KST<\/li>\n
        • Presentation Code\/Location:<\/strong> OP02-1\/Room D (Grand Ballroom)<\/li>\n<\/ul>\n<\/li>\n
        • KSMO 2026 Best Poster Presentation Award Ceremony<\/strong>\n
            \n
          • Date:<\/strong>September 4, 2026<\/li>\n
          • Time:<\/strong> 16:10\u201316:30 KST\/Room C (Grand Ballroom)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

             <\/p>\n

            \u201cKSMO and FACO bring together an important community of oncologists and clinical investigators from across Asia and internationally,\u201d said Dr. Luk<\/strong>. \u201cThe selection of HCB301 for oral presentation, together with two HCB101 presentations and the recognition of our gastric cancer work through the Best Poster Presentation Award, gives us an opportunity to present the growing clinical breadth of the FBDB\u2122 platform. We look forward to discussing these programs and their potential to expand the therapeutic possibilities of cancer immunotherapy.\u201d<\/p>\n

             <\/p>\n

            The KSMO presentations will highlight HCB101\u2019s clinical development in gastric cancer and HNSCC, including combination strategies with established anticancer therapies, as well as first-in-human clinical experience with HCB301 and its coordinated targeting of innate immune suppression, adaptive immune checkpoint signaling, and TGF\u03b2-mediated immune exclusion.<\/p>\n

             <\/p>\n

            Additional clinical data from the presentations will be shared following their presentation at KSMO 2026.<\/p>\n

            \u00a0<\/strong><\/p>\n

            About HCB101<\/strong><\/p>\n

            HCB101 is an investigational engineered SIRP\u03b1\u2013IgG4 Fc fusion protein developed using HanchorBio\u2019s proprietary FBDB\u2122 platform. HCB101 blocks CD47\u2013SIRP\u03b1 signaling and is designed to enhance macrophage-mediated antitumor immunity. It is being evaluated as monotherapy (NCT05892718) and in combinations (NCT06771622) across solid and hematologic malignancies. HCB101 has received U.S. FDA Orphan Drug Designation for gastric cancer.<\/p>\n

             <\/p>\n

            About HCB301<\/strong><\/p>\n

            HCB301 is an investigational tri-specific SIRP\u03b1\u2013PD-L1\u2013TGF\u03b2 IgG4 fusion protein designed to coordinately modulate innate immunity, adaptive immunity, and TGF\u03b2-mediated immune exclusion within a single therapeutic molecule. It is being evaluated in the ongoing first-in-human Phase 1 HCB301-101 study (NCT06487624).<\/p>\n

            \u00a0<\/strong><\/p>\n

            About HanchorBio<\/strong><\/p>\n

            HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases. Its proprietary\u00a0Fc-Based Designer Biologics (FBDB\u2122) platform\u00a0enables the engineering of multifunctional biologics designed to coordinately modulate complementary immune pathways.<\/p>\n

             <\/p>\n

            HanchorBio\u2019s pipeline includes clinical-stage programs HCB101 (a SIRP\u03b1-based innate immune checkpoint program) and HCB301 (a trispecific immunotherapy targeting SIRP\u03b1, PD-L1, and TGF-\u03b2 biology), as well as next-generation programs including HCB303 and additional candidates across oncology and immune-mediated diseases. With operations in Taiwan, China, and the United States, HanchorBio integrates therapeutic engineering, translational science, clinical development, and global regulatory execution. For more information, please visit HanchorBio.com.<\/p>\n

            \u00a0<\/strong><\/p>\n

            Forward-Looking Statements<\/strong><\/p>\n

            This press release contains forward-looking statements, including statements regarding the development of HCB303, the timing and potential submission of an IND, initiation and design of future clinical studies, potential therapeutic characteristics and mechanisms of HCB303, development of HanchorBio\u2019s pipeline, and the capabilities and potential of the FBDB\u2122 platform. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Regulatory feedback does not constitute approval of an IND or assurance that clinical development will proceed as planned. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.<\/p>\n","protected":false},"excerpt":{"rendered":"

            HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026\u2014the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference\u2014held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2\u20134, 2026, in Seoul, Korea.<\/p>\n","protected":false},"featured_media":2533,"template":"","news-category":[36,26],"class_list":["post-2534","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-events","news-category-development-progress"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2533"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2534"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}